Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12 Month Open-label Randomized Parallel Group Study to Investigate the Influence of Salmeterol Xinafoate/Fluticasone Propionate Either in Fixed Combination or Separately Via Diskus Inhalers on the Course of the Disease and Frequency of Exacerbations in Subjects With Severe and Very Severe COPD.
Brief Summary: This is a 12 month randomized, open-label, parallel-group study to obtain data on the frequency and variability of exacerbations in severe and very severe Chronic Obstructive Pulmonary Disease (COPD) patients (Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage III and IV) receiving salmeterol xinafoate and fluticasone propionate either in fixed combination (SFC) or from separate inhalers (Sal/FP) with standard therapy. 200 subjects will be enrolled in approximately 30 study centres in Germany. Data on health care utilisation will be collected to compare direct costs associated with COPD in these two groups.

Baseline data will be collected for all subjects at Visit 1 and eligible subjects will be randomized to receive either SFC 50/500 µg bid (twice daily) as fixed combination or Sal 50 µg bid (twice daily) and FP 500 µg bid (twice daily) concurrently over 52 weeks. Subjects will return for study visits every two to three months until week 52. Additional telephone calls will be made between scheduled visits every 4 weeks. Assessments will include monitoring of frequency of exacerbations, health care utilisation (including emergency visits and hospitalizations) and rescue medication, lung function, drug compliance, health-related quality of life (SGRQ = St George's Respiratory Questionnaire) and safety.


Options:
A: Arm Label: Treatment sequence I; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVA149, Drug: Placebo | Arm Label: Treatment sequence II; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVA149, Drug: Placebo | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): Treatment sequence I, Treatment sequence II | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Treatment sequence I, Treatment sequence II
B: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: 62.5/25mcg | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: 62.5mcg | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: 25mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 62.5/25mcg; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: 62.5mcg; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: 25mcg; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol / Fluticasone (50/500 µg) BID fixed combination | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers | Intervention Type: DRUG; Name: Salmeterol / Fluticasone (50/500 µg) BID fixed combination; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers; Assigned to Arm(s): arm 2
D: Arm Label: tiotropium+olodaterol low dose; Type: EXPERIMENTAL; Interventions: Device: Respimat inhaler, Drug: tiotropium+olodaterol (low dose) | Arm Label: tiotropium+olodaterol high dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium + olodaterol (high dose), Device: Respimat inhaler | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Respimat inhaler, Drug: placebo to tiotropium+olodaterol | Intervention Type: DEVICE; Name: Respimat inhaler; Assigned to Arm(s): tiotropium+olodaterol low dose | Intervention Type: DRUG; Name: tiotropium+olodaterol (low dose); Assigned to Arm(s): tiotropium+olodaterol low dose | Intervention Type: DRUG; Name: tiotropium + olodaterol (high dose); Assigned to Arm(s): tiotropium+olodaterol high dose | Intervention Type: DEVICE; Name: Respimat inhaler; Assigned to Arm(s): tiotropium+olodaterol high dose | Intervention Type: DEVICE; Name: Respimat inhaler; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: placebo to tiotropium+olodaterol; Assigned to Arm(s): placebo

Answer: C